Purpose Cardiogenic shock is associated with high mortality. In refractory shock, it is unclear
if mechanical circulatory support (MCS) devices improve survival. We conducted a network …

Background and Objectives: Post-infarct ventricular septal rupture (PIVSR) continues to
have significant morbidity and mortality, despite decreased prevalence. Impella and …

Background: The Impella® percutaneous left ventricular assist device has been available in
Japan since 2017. This is the first large-scale registry study to analyze the efficacy and …

Background Guidelines advocate the use of extracorporeal cardio-pulmonary resuscitation
with veno-arterial extracorporeal membrane oxygenation (VA-ECMO) in selected patients …

Aims We aimed to detail the early clinical experience with pVAD 5.5 at a large academic
medical centre. Impella® 5.5 (Abiomed) is a temporary peripherally inserted left ventricular …

In recent years, there have been significant advancements in the understanding, risk-
stratification, and treatment of cardiogenic shock (CS). Despite improved pharmacologic and …

Mechanical circulatory support (MCS) is used in cardiogenic shock for periprocedural
hemodynamic stability in high-risk patients and to support patients with symptomatic …

Thanks to advancements in percutaneous cardiac interventions, an expanding patient
population now qualifies for treatment through percutaneous endovascular procedures …

The function of the right ventricle (RV) is to drive the forward flow of blood to the pulmonary
system for oxygenation before returning to the left ventricle. Due to the thin myocardium of …

Abstract Purpose The Impella device historically required a heparin-based purge solution to
reduce the risk of biomaterial deposition to maintain pump function. In April 2022, the Food …